These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27578429)

  • 1. Effect of Treatment Duration and Frequency on Uremic Solute Kinetics, Clearances and Concentrations.
    Leypoldt JK; Meijers BK
    Semin Dial; 2016 Nov; 29(6):463-470. PubMed ID: 27578429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?
    Eloot S; Van Biesen W; Glorieux G; Neirynck N; Dhondt A; Vanholder R
    PLoS One; 2013; 8(11):e76838. PubMed ID: 24236005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sad but forgotten truth: the story of slow-moving solutes in fast hemodialysis.
    Eloot S; Van Biesen W; Vanholder R
    Semin Dial; 2012; 25(5):505-9. PubMed ID: 22925227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple method for the calculation of dialysis Kt factor as a quantitative measure of removal efficiency of uremic retention solutes: Applicability to high-dialysate vs low-dialysate volume technologies.
    Colussi G; Brunati CCM; Gervasi F; Montoli A; Vergani D; Curci F; Minetti E
    PLoS One; 2020; 15(5):e0233331. PubMed ID: 32469929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obstacles to reducing plasma levels of uremic solutes by hemodialysis.
    Sirich TL
    Semin Dial; 2017 Sep; 30(5):403-408. PubMed ID: 28558415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in protein-bound solutes unacceptable as marker of dialysis efficacy during alternate-night nocturnal hemodialysis.
    Meijers B; Toussaint ND; Meyer T; Bammens B; Verbeke K; Vanrenterghem Y; Kerr PG; Evenepoel P
    Am J Nephrol; 2011; 34(3):226-32. PubMed ID: 21791919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.
    Etinger A; Kumar SR; Ackley W; Soiefer L; Chun J; Singh P; Grossman E; Matalon A; Holzman RS; Meijers B; Lowenstein J
    PLoS One; 2018; 13(2):e0192770. PubMed ID: 29470534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of increased frequency of hemodialysis on serum cystatin C and β2-microglobulin concentrations: A secondary analysis of the frequent hemodialysis network (FHN) trial.
    Huang SS; Kaysen GA; Levin NW; Kliger AS; Beck GJ; Rocco MV; Filler G; Lindsay RM;
    Hemodial Int; 2019 Jul; 23(3):297-305. PubMed ID: 30861262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysis dosing for chronic hemodialysis: beyond Kt/V.
    Daugirdas JT
    Semin Dial; 2014 Mar; 27(2):98-107. PubMed ID: 24738145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms.
    Bammens B; Evenepoel P; Verbeke K; Vanrenterghem Y
    Kidney Int; 2003 Dec; 64(6):2238-43. PubMed ID: 14633148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of intradialytic exercise on hemodialysis adequacy: A systematic review.
    Kirkman DL; Scott M; Kidd J; Macdonald JH
    Semin Dial; 2019 Jul; 32(4):368-378. PubMed ID: 30968465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial.
    Sirich TL; Fong K; Larive B; Beck GJ; Chertow GM; Levin NW; Kliger AS; Plummer NS; Meyer TW;
    Kidney Int; 2017 May; 91(5):1186-1192. PubMed ID: 28089366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily hemodialysis efficiency: an analysis of solute kinetics.
    Depner TA
    Adv Ren Replace Ther; 2001 Oct; 8(4):227-35. PubMed ID: 11593488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the Middle Molecule Hypothesis of Uremic Toxicity: A Systematic Review of Beta 2 Microglobulin Population Kinetics and Large Scale Modeling of Hemodialysis Trials In Silico.
    Roumelioti ME; Nolin T; Unruh ML; Argyropoulos C
    PLoS One; 2016; 11(4):e0153157. PubMed ID: 27055286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual Function Effectively Controls Plasma Concentrations of Secreted Solutes in Patients on Twice Weekly Hemodialysis.
    Leong SC; Sao JN; Taussig A; Plummer NS; Meyer TW; Sirich TL
    J Am Soc Nephrol; 2018 Jul; 29(7):1992-1999. PubMed ID: 29728422
    [No Abstract]   [Full Text] [Related]  

  • 16. Adequacy in dialysis: intermittent versus continuous therapies.
    Misra M; Nolph KD
    Nefrologia; 2000; 20 Suppl 3():25-32. PubMed ID: 10835874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kt/V (and especially its modifications) remains a useful measure of hemodialysis dose.
    Daugirdas JT
    Kidney Int; 2015 Sep; 88(3):466-73. PubMed ID: 26176827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solute clearances and fluid removal in the frequent hemodialysis network trials.
    Greene T; Daugirdas JT; Depner TA; Gotch F; Kuhlman M; ; ;
    Am J Kidney Dis; 2009 May; 53(5):835-44. PubMed ID: 19339093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volume of urea cleared as a therapy dosing guide for more frequent hemodialysis.
    Leypoldt JK; Weinhandl ED; Collins AJ
    Hemodial Int; 2019 Jan; 23(1):42-49. PubMed ID: 30255600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In search of ideal hemodialysis: is prolonged frequent dialysis the answer?
    Raj DS; Charra B; Pierratos A; Work J
    Am J Kidney Dis; 1999 Oct; 34(4):597-610. PubMed ID: 10516338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.